A Randomized, Multicenter, Double-Masked, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Vancomycin Hydrochloride Ophthalmic Ointment 1.1% in Patients With Moderate to Severe Bacterial Conjunctivitis
Phase: PHASE3
Conditions: Bacterial Conjunctivitis
Sponsor: Kurobe LLC

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
1 
 
 
  
 
CLINICAL TRIAL PROTOCOL KUR-1301-101 
A RANDOMIZED, MULTICENTER, DOUBLE-MASKED, 
PLACEBO-CONTROLLED, PHASE 3 STUDY TO 
EVALUATE THE SAFETY AND EFFICACY OF 
VANCOMYCIN HYDROCHLORIDE OPHTHALMIC 
OINTMENT 1.1% IN PATIENTS WITH MODERATE TO 
SEVERE BACTERIAL CONJUNCTIVITIS  
 
Study Phase: 
Phase 3 
Product Name: 
Vancomycin hydrochloride ophthalmic ointment 
Indication: 
Bacterial conjunctivitis 
Sponsor: 
Kurobe, LLC 
400 N Ashley Drive Suite 2150 
Tampa, FL 33602 
Medical Monitor: 
Charles Slonim, MD 
Original Protocol: 
10 March 2015 
Amendment 1: 
03 May 2016 
Amendment 2: 
15 September 2016 
 
 
 
CONFIDENTIAL 
The information contained in this document is confidential and proprietary property of Kurobe, 
LLC. Neither this document nor the information contained herein may be divulged, transmitted, 
reproduced, published, or otherwise used by others without the express written permission of 
Kurobe, LLC. Investigators are cautioned that the information given in this brochure might be 
subject to change and revision. Any conclusion regarding efficacy and safety must be considered 
provisional. 
 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
3 
 
 
  
 
INVESTIGATOR’S AGREEMENT 
 
Study Title: 
A Randomized, Multicenter, Double-Masked, Placebo-Controlled, 
Phase 3 Study to Evaluate the Safety and Efficacy of Vancomycin 
Hydrochloride Ophthalmic Ointment 1.1% in Patients with 
Moderate to Severe Bacterial Conjunctivitis 
Study Number: 
KUR-1301-101 
Original Protocol: 
10 March 2015 
Amendment 1: 
03 May 2016 
Amendment 2: 
15 September 2016 
 
I have read the KUR-1301-101 protocol. The signature below constitutes the approval of this 
protocol and the attachments, and provides the necessary assurances that this trial will be 
conducted according to all stipulations of the protocol, including all statements regarding 
confidentiality, and in compliance with International Conference of Harmonisation (ICH) 
Guidelines, and all applicable United States (US) Federal Regulations and local legal and 
regulatory requirements. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Printed Name of Investigator 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signature of Investigator 
 
 
 
 
 
 
 
 
Date 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
4 
 
 
  
 
PROCEDURES IN CASE OF EMERGENCY 
Table 1: 
Emergency Contact Information 
Role in Study 
Name 
Contact Information 
Clinical Study Leader 
Roselyn Judd 
Oculos Clinical Research 
615-962-8698 (Office) 
586-212-0237 (Mobile) 
Email: rjudd@pointguardllc.com 
Medical Monitor 
Charles Slonim, MD 
Oculos Clinical Research 
813-690-0255 (Mobile) 
813-443-5865 (Fax) 
Email: cslonim@pointguardllc.com 
 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
5 
 
 
  
 
1. 
SYNOPSIS 
Name of Sponsor/Company: Kurobe, LLC 
Name of Investigational Product: Vancomycin hydrochloride ophthalmic ointment 1.1%  
Name of Active Ingredient: Vancomycin hydrochloride 
Title of Study: A Randomized, Multicenter, Double-Masked, Placebo-Controlled, Phase 3 Study to 
Evaluate the Safety and Efficacy of Vancomycin Hydrochloride Ophthalmic Ointment 1.1% in Patients 
with Moderate to Severe Bacterial Conjunctivitis. 
Studied Period (Years):  
Estimated date first patient enrolled: August 2015  
Estimated date last patient completed: November 2016 
Phase of Development:  
3 
Objectives: The primary objective of this study is to evaluate the safety and efficacy of vancomycin 
hydrochloride ophthalmic ointment 1.1% dosed 4 times daily (QID) in patients with moderate to severe 
Gram-positive bacterial conjunctivitis.  
Methodology: This will be a randomized, multicenter, double-masked, placebo-controlled study. 
Eligible subjects will enter the study with clinically diagnosed bacterial conjunctivitis.  
At Screening/Visit 1 (Day 1), subjects will undergo AdenoPlus® conjunctival adenovirus screening 
testing. If the AdenoPlus test result is negative, the subject will undergo microbial culture (including 
susceptibility testing) and ophthalmic evaluations. If the AdenoPlus® test result is positive, the subject 
will be considered a screen failure. Subjects confirmed to have met eligibility criteria will be 
randomized to 1 of 2 treatment arms and will administer the allocated study medication 4 times daily 
(QID) to the infected eye(s) approximately 4 hours apart for 7 days: 
• 
Vancomycin ophthalmic ointment 1.1% QID 
• 
Vehicle ointment (placebo) QID 
If both eyes are being treated, the eye with more severe signs of infection (based on the sum of the 3 
grading scales [conjunctival discharge, bulbar conjunctival injection, and palpebral conjunctival 
injection]) will be considered the study eye. If the sum of the scales for both eyes are equal, the default 
will be the right eye. If a subject with a unilateral infection develops an infection in the contralateral 
eye, the subject should contact the clinical site and will be instructed to treat the contralateral eye with 
the study medication if signs of ocular conjunctival discharge and/or injection are present. The eye 
originally treated will continue to be considered the study eye. Only the study eye will be assessed for 
efficacy; safety assessments will be conducted bilaterally. 
At Visit 2 (Day 5) subjects will return to the clinical site, and microbial culture and ophthalmic 
evaluations of safety and efficacy will be conducted.  
 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
6 
 
 
  
 
 
Methodology (continued): 
At Visit 3 (Day 8) subjects will return to the clinical site for final microbial culture, and ophthalmic 
evaluations of safety and efficacy. 
Randomized study medication (vancomycin or vehicle [placebo] ophthalmic ointment) will be 
provided in identical-appearing tubes. The identity of the study medications will be masked to the 
subject, Investigator, study personnel responsible for ophthalmic evaluations, and sponsor personnel 
responsible for medical evaluation of the data. 
Number of Patients (Planned): Subjects will be enrolled at approximately 20 clinical sites, until the 
number of Gram-positive subjects has reached at least 75 per group. 
Inclusion Criteria: 
1. Age 1 and older 
2. Clinical diagnosis of acute bacterial conjunctivitis with at least one eye exhibiting conjunctival 
discharge graded ≥ 2 as well as palpebral conjunctival injection graded ≥ 2 AND bulbar 
conjunctival injection graded ≥ 2 with onset ≤ 4 days as reported by the subject. 
3. Negative test result on AdenoPlus® adenovirus test. 
4. Snellen visual acuity (VA) equal to or better than 20/200 in each eye using current corrective 
lenses, if required (or if worn) and/or using a pinhole if subject’s corrective lenses are not 
available at the time of exam. Every attempt should be made to obtain a VA measurement in 
children and, if it is unobtainable, the decision as to whether the criterion is met will be at the 
investigator’s discretion. 
5. Female subjects must be 1-year postmenopausal, surgically sterilized, or women of 
childbearing potential with a negative urine pregnancy test at Visit 1. Women of childbearing 
potential must use an acceptable form of contraception throughout the study. Acceptable 
methods include the use of at least one of the following: intrauterine (intrauterine device), 
hormonal (oral, injection, patch, implant, ring), barrier with spermicide (condom, diaphragm), 
or abstinence. 
6. Able to self-administer study medication or to have the study medication administered by a 
caregiver throughout the study period. 
7. Must have signed written consent from the subject prior to participation in any study-related 
procedures if the subject is 18 years of age or older, or from the legally authorized 
representative/guardian if the subject is under 18 years of age. 
8. Must have the signature of the subject on the assent form, as required by Institutional Review 
Board (IRB) guidelines, if the subject is under 18 years of age. 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
7 
 
 
  
 
Exclusion Criteria:  
1. Suspected viral or allergic conjunctivitis or suspected fungal or acanthamoeba infections at 
Screening in either eye. 
2. Suspected iritis/uveitis or episcleritis/scleritis at Screening in either eye or history of either 
condition. 
3. Active ulcerative keratitis, specifically any epithelial loss greater than punctate keratitis (eg, 
confluent epithelial loss or any subepithelial infiltration) in either eye. 
4. History of recurrent corneal erosion syndrome, either idiopathic or secondary to previous 
corneal trauma or dry eye syndrome in study eye. 
5. Uncontrolled systemic or debilitating disease (eg, cardiovascular disease, hypertension, 
diabetes, or cystic fibrosis) in the opinion of the Investigator. 
6. Subjects who are immunocompromised (eg, HIV-positive); any use of immunosuppressive 
therapy (including chemotherapy). 
7. Any use of topical ophthalmic medications, including tear substitutes, within 2 hours before 
Screening and throughout the study period in either eye. 
8. Use of topical ophthalmic antimicrobial therapy within 48 hours prior to Screening. Use of 
topical ophthalmic antimicrobial therapy other than study medication is prohibited throughout 
the study period in either eye. 
9. Use of topical ophthalmic anti-inflammatory agents (eg, nonsteroidal anti-inflammatory drugs 
[NSAIDs] or steroids, including steroid-antibiotic combinations) within 48 hours prior to 
Screening and throughout the study period in either eye. 
10. Use of systemic antimicrobial therapy for active respiratory tract, urinary tract, skin/soft tissue, 
or otitis media infection within 72 hours prior to Screening and throughout the study period. 
Use of a topical dermatologic antibiotic is permitted. 
11. Use of systemic steroids within 14 days of screening and throughout the study period. Inhaled, 
intranasal, and topical dermatological steroids are permitted. 
12. Contact lens wear during the study period in study eye. (contact lens wear in an untreated 
fellow eye is allowed). 
13. Ocular surgery (nonlaser or laser) within 6 weeks prior to Screening in study eye. 
14. Pregnancy or lactation. 
15. Participation in an ophthalmic drug or device research study within 30 days prior to Screening 
in either eye. 
16. Known hypersensitivity to vancomycin, petrolatum, or mineral oil. 
Investigational Product, Dosage and Mode Of Administration: Vancomycin ophthalmic ointment 
1.1%, approximately 1 cm of ointment QID, topical ocular administration for 7 days 
Reference Therapy, Dosage and Mode Of Administration: Ophthalmic ointment vehicle (placebo), 
approximately 1 cm of ointment QID, topical ocular administration for 7 days 
Duration of Treatment: 7 days 
Study Procedures: 
Visit 1 (Day 1): Screening/Baseline At Visit 1 subjects will provide informed consent/assent before 
any study-related procedures are conducted and participate in screening procedures (AdenoPlus® 
conjunctival adenovirus test, microbial culture, ophthalmic assessments including grading of clinical 
signs) to establish eligibility for the study.  
 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
8 
 
 
  
 
Study Procedures (continued): 
Eligible subjects will be randomized into the study, study medication will be dispensed, and subjects 
(or caregivers) will receive instruction and then administer the first dose of allocated study medication 
at the site. 
All 4 doses should be administered on Day 1 even if the intervals are shorter than 4 hours between 
doses. On Days 2-7 subjects will continue to administer the randomized study medication QID 
(approximately 4 hours between doses). 
Subjects should be reminded to bring the study diary to the clinical site at Visit 2 (Day 5). 
Visit 2 (Day 5): At Visit 2, Day 5 (± 1 day) study site personnel will conduct diary review. Subjects 
will participate in microbial culture and ophthalmic assessments of safety and efficacy. 
Subjects must be reminded not to dose after their fourth dose on Day 7 and to bring all study 
medication materials and the study diary to the clinical site at Visit 3 (Day 8). 
Visit 3 (Day 8): At Visit 3, Day 8 (+ 1 day) subjects will return all study medication to the clinical site. 
Study site personnel will conduct diary review and study drug accountability procedures. Subjects will 
participate in final ophthalmic assessments of safety and efficacy. 
If the subject continues to show signs of infection in either eye at Day 8, the subject will be treated per 
the Investigator’s standard of care. Study treatment will not be administered after the last dose on Day 
7. 
Efficacy Assessments: Efficacy will be assessed by the investigator’s grading of 3 clinical signs on 4 
point scales: Conjunctival discharge on a scale of 0 3 (where 0 is absent and 3 is severe), and bulbar 
conjunctival injection and palpebral conjunctival injection each graded separately on a scale of  0 3 
(where 0 is none and 3 is severe),  as well as by microbial culture. 
Safety Assessments: Safety will be assessed by Snellen visual acuity, biomicroscopy, and adverse 
event assessment. 
Criteria for Evaluation: The primary endpoints comprise a set of hypotheses that will be tested in a 
hierarchical fashion. 
Primary Efficacy Endpoint: Proportion of subjects at Visit 3 (Day 8) with: 
• 
Clinical resolution of bacterial conjunctivitis (defined as absence of conjunctival discharge, 
bulbar conjunctival injection and palpebral conjunctival injection) 
• 
Microbial eradication (absence of all Gram-positive bacterial species present at baseline) 
The difference in proportion in the two treatment groups will be tested by the chi-square test with a 
significance level of 0.05. In order to control the Type I error rate these two endpoints will be tested 
sequentially in the order described above. If the null hypothesis for the clinical resolution endpoint can 
be rejected at P ≤ 0.05, the bacterial eradication endpoint will be tested at P ≤ 0.05 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
9 
 
 
  
 
Statistical Methods: Primary efficacy analysis will be conducted on the modified intent-to-treat 
(mITT) population, which will consist of randomized subjects with Gram-positive bacterial 
conjunctivitis. Efficacy analysis will also be conducted on the intent-to-treat (ITT) population, which 
will consist of all randomized subjects. Per protocol (PP) analysis will be conducted on those subjects 
in the mITT population who are compliant in dosing, meeting study visits, and without significant 
protocol violations. Safety analyses will be performed using the safety analysis set (all randomized 
subjects who received at least one dose of the allocated product). 
The analysis of continuous and ordinal variables will use the applicable parametric methods (t-test, 
analysis of variance [ANOVA], and analysis of covariance [ANCOVA]). Descriptive statistics will be 
used to summarize continuous outcomes (number of subjects [N], mean, standard deviation or standard 
error of the mean, median, maximum, and minimum) and categorical variables (frequency and 
percentage) at each assessment time point. 
Sample Size: Subjects will be enrolled until the number of subjects with Gram-positive bacterial 
conjunctivitis has reached at least 75 per group. A two-group chi-square test with a 0.05 two-sided 
significance level will have 90% power to detect the difference between a Group 1 proportion of 0.75 
and a Group 2 proportion of 0.50 (odds ratio of 3.0) when the sample size in each group is 77. 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
10 
 
  
Table 2: 
Schedule of Procedures 
Assessment 
Screening/Baseline  
Treatment 
End of 
Treatment 
Early 
Termination 
Day 
Day 1 
Day 5  
(± 1 day) 
Day 8 
(+ 1 day) 
Visit 
1 
2 
3 
 
Informed consent 
X 
 
 
 
Demographics 
X 
 
 
 
Medical/ocular history 
X 
 
 
 
Prior/concomitant medications 
X 
X 
X 
X 
Study diary review 
 
X 
X 
X 
AdenoPlus® conjunctival 
adenovirus test  
X 
 
 
 
Snellen visual acuity 
X 
X 
X 
X 
Biomicroscopy 
X 
X 
X 
X 
Grading of conjunctival discharge  
X 
X 
X 
X 
Grading of bulbar conjunctival 
injection 
X 
X 
X 
X 
Grading of palpebral conjunctival 
injection 
X 
X 
X 
X 
Microbial culture/susceptibility 
testing 
X 
X 
X 
X 
Urine pregnancy test 
X 
 
X 
X 
Inclusion/exclusion review 
X 
 
 
 
Randomization 
X 
 
 
 
Dispense study medication  
X 
 
 
 
Study medication administration at 
site 
X 
 
 
 
Adverse event assessment 
X 
X 
X 
X 
Collect opened and unopened study 
medication 
 
  
X 
X 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
11 
 
  
2. 
TABLE OF CONTENTS AND LIST OF TABLES  
TABLE OF CONTENTS 
1. 
SYNOPSIS ...................................................................................................................5 
2. 
TABLE OF CONTENTS AND LIST OF TABLES ..................................................11 
3. 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS.............................15 
4. 
INTRODUCTION ......................................................................................................16 
4.1. 
Background Information .............................................................................................16 
4.2. 
Rationale and Development for the Treatment of Moderate to Severe 
Bacterial Conjunctivitis ..............................................................................................16 
4.3. 
Justification for Dose, Regimen, and Treatment Period .............................................18 
4.4. 
Good Clinical Practices Statement .............................................................................19 
4.5. 
Population to Be Studied ............................................................................................19 
5. 
TRIAL OBJECTIVES AND PURPOSE ....................................................................20 
5.1. 
Primary Objective .......................................................................................................20 
6. 
INVESTIGATIONAL PLAN .....................................................................................21 
6.1. 
Overall Study Design ..................................................................................................21 
6.2. 
Number of Subjects ....................................................................................................21 
6.3. 
Criteria for Study Termination ...................................................................................21 
7. 
SELECTION AND WITHDRAWAL OF SUBJECTS ..............................................22 
7.1. 
Subject Inclusion Criteria ...........................................................................................22 
7.2. 
Subject Exclusion Criteria ..........................................................................................22 
7.3. 
Withdrawal Criteria ....................................................................................................23 
8. 
TREATMENT OF SUBJECTS ..................................................................................24 
8.1. 
Description of Study Drug ..........................................................................................24 
8.2. 
Randomization and Masking ......................................................................................24 
8.2.1. 
Unmasking During the Study Period ..........................................................................24 
8.3. 
Concomitant Medications ...........................................................................................25 
8.3.1. 
Permitted Medications and Treatments ......................................................................25 
8.3.2. 
Prohibited Medications ...............................................................................................25 
8.4. 
Treatment Compliance ................................................................................................25 
8.5. 
Discontinuation of Study Medication .........................................................................26 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
12 
 
  
8.6. 
Study Medication Materials and Management ...........................................................26 
8.6.1. 
Packaging and Labeling ..............................................................................................26 
8.6.2. 
Storage ........................................................................................................................26 
8.6.3. 
Administration ............................................................................................................26 
8.6.4. 
Study Drug Accountability .........................................................................................27 
9. 
STUDY ASSESSMENTS ..........................................................................................28 
9.1. 
Demographic and Background Characteristics ..........................................................28 
9.1.1. 
Demographic/Medical History ...................................................................................28 
9.1.2. 
Concomitant Medications History ..............................................................................28 
9.1.3. 
Ophthalmic History and Ophthalmic Intervention History ........................................28 
9.1.4. 
Urine Pregnancy Test .................................................................................................28 
9.2. 
Efficacy Assessments .................................................................................................28 
9.2.1. 
Assessment of Clinical Resolution .............................................................................28 
9.2.1.1. 
Ocular Discharge ........................................................................................................28 
9.2.1.2. 
Bulbar Conjunctival Injection .....................................................................................29 
9.2.1.3. 
Palpebral Conjunctival Injection ................................................................................29 
9.2.1.4. 
Bulbar and Palpebral Conjunctival Injection ..............................................................29 
9.2.2. 
Assessment of Bacterial Eradication ..........................................................................29 
9.3. 
Safety Assessments .....................................................................................................29 
9.3.1. 
Snellen Visual Acuity Assessment .............................................................................29 
9.3.2. 
Biomicroscopy ............................................................................................................30 
9.4. 
Diagnostic Assessments ..............................................................................................30 
9.4.1. 
AdenoPlus® Test .........................................................................................................30 
9.5. 
Adverse and Serious Adverse Events .........................................................................30 
9.5.1. 
Definition of Adverse Events .....................................................................................30 
9.5.1.1. 
Adverse Event (AE) ....................................................................................................30 
9.5.1.2. 
Serious Adverse Event (SAE) ....................................................................................30 
9.6. 
Relationship to Study Drug ........................................................................................31 
9.7. 
Recording Adverse Events .........................................................................................31 
9.8. 
Reporting Adverse Events ..........................................................................................32 
10. 
STUDY ACTIVITIES ................................................................................................34 
10.1. 
Visit 1 (Day 1)/Screening/Baseline ............................................................................34 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
13 
 
  
10.2. 
Visit 2/Treatment ........................................................................................................35 
10.3. 
Visit 3/End of Treatment ............................................................................................35 
10.4. 
Early Discontinuation .................................................................................................36 
11. 
STATISTICS ..............................................................................................................37 
11.1. 
General Considerations ...............................................................................................37 
11.2. 
Determination of Sample Size ....................................................................................37 
11.3. 
Analysis Populations ..................................................................................................38 
11.3.1. 
Populations for Efficacy Analysis ..............................................................................38 
11.3.1.1. 
Intent-to-Treat (ITT) Population .................................................................................38 
11.3.1.2. 
Modified Intent-to-Treat (mITT) Population ..............................................................38 
11.3.2. 
Per Protocol Analyses .................................................................................................38 
11.3.3. 
Population for Safety Analysis ...................................................................................38 
11.4. 
Demographics and Baseline Characteristics ...............................................................38 
11.5. 
Efficacy Analysis ........................................................................................................38 
11.5.1. 
Primary Endpoint ........................................................................................................38 
11.6. 
Safety Analyses ..........................................................................................................39 
12. 
QUALITY CONTROL AND QUALITY ASSURANCE .........................................40 
13. 
ADMINISTRATIVE CONSIDERATIONS ..............................................................41 
13.1. 
Institutional Review Board (IRB) ...............................................................................41 
13.2. 
Ethical Conduct of the Study ......................................................................................41 
13.3. 
Written Informed Consent ..........................................................................................41 
13.4. 
Subject Confidentiality and Confidentiality of Data ..................................................41 
13.5. 
Study Monitoring ........................................................................................................42 
13.6. 
Case Report Forms and Study Records ......................................................................42 
13.7. 
Protocol Violations/Deviations ...................................................................................42 
13.8. 
Access to Source Documentation ...............................................................................43 
13.9. 
Data Generation and Analysis ....................................................................................43 
13.9.1. 
Retention of Data ........................................................................................................43 
13.10. 
Publication And Disclosure Policy .............................................................................43 
14. 
LIST OF REFERENCES ............................................................................................44 
 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
14 
 
  
LIST OF TABLES 
Table 1: 
Emergency Contact Information ...................................................................................4 
Table 2: 
Schedule of Procedures ...............................................................................................10 
Table 3: 
Abbreviations ..............................................................................................................15 
 
 
  

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
15 
 
  
3. 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
The following abbreviations are used in this study protocol. 
Table 3: 
Abbreviations  
Abbreviation 
Explanation 
AE 
Adverse event 
ADR 
Adverse drug reaction 
ANCOVA 
Analysis of covariance 
ANOVA 
Analysis of variance 
CI 
Confidence interval 
GCP 
Good Clinical Practice 
eCRF 
Electronic case report form 
FDA 
Food and Drug Administration 
ICH 
International Conference on Harmonization 
IEC 
Independent Ethics Committee 
IRB 
Institutional Review Board 
ITT 
Intent-to-treat 
IWRS 
Interactive web response system 
LOCF 
Last observation carried forward 
mITT 
Modified intent-to-treat 
MR-CoNS 
Methicillin-resistant coagulase-negative staphylococci 
MRSA 
Methicillin-resistant Staphylococcus aureus 
MRSE 
Methicillin-resistant Staphylococcus epidermidis 
NSAID 
Nonsteroidal anti-inflammatory drug 
QID 
Four times daily 
SAE 
Serious adverse event 
SOP 
Standard operating procedure 
VA 
Visual acuity 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
16 
 
  
4. 
INTRODUCTION 
4.1. 
Background Information 
Vancomycin ointment 1.1% is a topical ophthalmic antibiotic ointment being investigated for the 
treatment of moderate to severe bacterial conjunctivitis, including infections caused by 
methicillin-resistant Staphylococcus aureus (MRSA)/methicillin-resistant Staphylococcus 
epidermidis (MRSE). The initial nonclinical and clinical development of this product was 
conducted by Toa Pharmaceutical Co., Ltd (Toa), of Toyama, Japan and the product was 
approved in Japan by the Pharmaceuticals and Medical Devices Agency (PMDA) in 2009. An 
extensive database comprising 100% of the patients treated with the drug since its approval was 
maintained by Toa as a post-approval commitment. 
4.2. 
Rationale and Development for the Treatment of Moderate to Severe 
Bacterial Conjunctivitis 
External ocular infections such as those caused by MRSA or MRSE frequently are not serious 
but in rare cases may be severe enough to threaten vision. Sight-threatening eye infections 
caused by MRSA, including bilateral blindness from orbital cellulitis, panophthalmitis, and 
complete corneal flap melt after laser-assisted in situ keratomileusis (LASIK) have been reported 
(Rutar et al, 2005; Rutar et al, 2006; Rubinfeld and Negvesky, 2001). In a case study of 
3 patients with endogenous endophthalmitis caused by MRSA, 2 of the 3 patients experienced 
blindness in the affected eye and in the third patient, the affected eye had to be enucleated 
(Ness and Schneider, 2009). 
When ocular infections due to resistant organisms such as MRSA/MRSE do not respond to 
empiric treatment with approved antibiotics, there are few treatment options, as methicillin 
resistance has been shown to be a marker for multidrug resistance (resistance to ≥4 antibiotic 
classes) (Asbell et al, 2008a; Haas et al, 2011). Both MRSA and methicillin-resistant 
coagulase-negative staphylococci (MR-CoNS, including Staphylococcus epidermidis) isolates in 
one study showed considerable resistance to fluoroquinolones (ciprofloxacin, levofloxacin, 
gatifloxacin, and moxifloxacin), macrolides (azithromycin), β-lactams (penicillin), polypeptides 
(polymyxin B) and aminoglycosides (Asbell et al, 2008a). Trimethoprim was the only agent 
tested that showed activity against MRSA (vancomycin was not tested in this study). These 
results are consistent with an earlier analysis of surveillance data that showed an increasing 
prevalence of MRSA strains resistant to multiple antibiotics, including all available 
fluoroquinolones (Asbell et al, 2008b). In another study among MRSA and MR-CoNS isolates, 
46.5% and 58.3% of isolates, respectively, were resistant to ≥2 antibiotic classes and 11.5% and 
6.3%, respectively, were resistant to 5 different drug classes, including the fluoroquinolones. 
Only vancomycin, a member of the glycopeptides class of antibiotics, was active against all 
methicillin-resistant isolates (Haas et al, 2011).  
The importance of treatment options for multidrug resistant ocular infections is indicated by the 
increasing incidence of ocular infections caused by MRSA and MRSE (Cavuoto et al, 2007; 
Blomquist, 2006; Freidlin et al, 2007; Adebayo et al, 2011; Asbell et al, 2008b; Asbell et al, 
2008a; Haas et al 2011), including a significant proportion of cases in the community setting 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
17 
 
  
(Klevens et al, 2007; Blomquist, 2006; Miller et al, 2006). In addition to the surveillance study 
demonstrating the activity of vancomycin against all methicillin-resistant isolates (Haas et al, 
2011), other case reports in the literature report successful treatment with vancomycin of several 
types of external ocular infections due to MRSA or MRSE, including conjunctivitis, corneal 
ulcers, keratitis, blepharitis, meibomianitis, dacryocystitis, and blepharoconjunctivitis 
(Brennen and Muder, 1990; Eiferman et al, 1991; Lee et al, 2010; Rubinfeld and Negvesky, 
2001; Sotozono et al, 2002; Solomon et al, 2007; Ong et al, 2013; Sotozono et al, 2013; Khan et 
al, 1984; Fleischer et al, 1986; Goodman and Gottsch, 1988). 
Nonclinical studies demonstrated that the bactericidal action of vancomycin against S. aureus 
and the vegetative cells of Clostridium difficile results primarily from inhibition of cell-wall 
biosynthesis. In addition, vancomycin alters bacterial-cell-membrane permeability and 
ribonucleic acid (RNA) synthesis (Vancocin package insert, 2011). 
Antibiotic sensitivity profiles suggest that vancomycin is the drug of choice to treat ocular 
infections due to MRSA/MRSE, but there currently is no approved ophthalmic formulation of 
vancomycin in the United States. Current ophthalmic vancomycin treatments must therefore be 
compounded. The inherent risks of compounding in general were well publicized during 2012, 
when contaminated methylprednisone acetate from the New England Compounding Center 
caused an outbreak of fungal meningitis that killed 64 people in 20 states. Furthermore, the 
solution used for compounding can affect the tolerability of the treatment. For example, 
Fleischer and colleagues reported treatment of 2 patients with severe MRSE 
blepharoconjunctivitis with topical vancomycin hydrochloride prepared with sterile water, which 
they indicated caused significant ocular irritation likely due to the low pH and osmolality values. 
An alternate solution with phosphate-buffered artificial tears was rated more tolerable than sterile 
water or saline-based solutions by 10 healthy volunteers, but it retained antimicrobial activity for 
only 2 weeks (Fleischer et al, 1986). 
A more stable vancomycin formulation is particularly desirable for outpatients, who are likely to 
comprise a substantial proportion of patients seeking treatment for MRSA/MRSE infections. 
MRSA/MRSE infections were once considered primarily a nosocomial infection. However, 
MRSA has recently (since at least 2005) been found to be more associated with community onset 
(~70%) than hospital onset (~30%) (Klevens et al, 2007; Blomquist, 2006). It is therefore 
anticipated that a substantial number of patients with ocular MRSA/MRSE will be treated in an 
outpatient setting. 
One previous study of the stability of vancomycin ophthalmic solution compounded in artificial 
tears reported that while the solution was stable for 45 days when stored at -10°C, at room 
temperature (25°C) it was stable for only 7 days and retained less than 85% of the original 
vancomycin concentration at 10 days (Fuhrman and Stroman, 1998). Vancomycin eye drops 
prepared in sodium chloride 0.9% were stable to 21 days at 4°C and 15 days at 25°C (Barbault et 
al, 1999). Another study demonstrated vancomycin ophthalmic solution in 5% glucose was 
stable for 3 months when frozen at -20°C (Sautou-Miranda et al, 2002). 
The vancomycin ointment 1.1% that is presently being investigated is formulated in a white 
petrolatum and mineral oil base, common in commercially-available ophthalmic ointments. It is 
stable for 3 years when stored at 2-8°C in an aluminum tube. 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
18 
 
  
Nonclinical studies of vancomycin ointment 1.1% administered four times daily (QID) suggest a 
good efficacy and safety profile, Studies in pigmented rabbits show rapid transport of 
vancomycin to the cornea and conjunctiva, with low-to-no concentrations in the aqueous humor. 
A published study in pigmented rabbits suggested that vancomycin concentrations were more 
widely distributed after Bacillus subtilis-induced ocular infection as compared with normal 
rabbits, however, a characteristic which may enhance rapid onset and prolong the duration of the 
vancomycin antimicrobial effect in infected eyes (Fukuda et al, 2003). Vancomycin was not 
detected in the serum of either the normal or infected rabbits, however. These results are 
consistent with a Phase 1 clinical study in healthy volunteers, in which the concentration of 
vancomycin was below the limits of quantitation (BLQ) in all subjects, after both single-dose 
and repeated-dose administration. These results suggest that systemic exposure to vancomycin is 
likely to be low, with few or no systemic effects. 
In a Phase 3 clinical study in patients with extraocular bacterial infections due to MRSA and 
MRSE that were refractory to at least a 3-day course of a topical fluoroquinolone, overall rates of 
bacterial eradication at end of treatment or discontinuation were 68.8% (11/16) for MRSA and 
100% (2/2) for MRSE, in the per protocol set (PPS). In a postmarketing surveillance (PMS) 
database analysis, among the subset of patients who were culture-positive for MRSA/MRSE and 
who had documented treatment failure on previous antibiotics and who received vancomycin as 
monotherapy, overall rates of bacterial eradication were 65.0% (106/163) for MRSA and 80.0% 
(16/20) for MRSE. The overall clinical response rate was 66.7% and for conjunctivitis (the most 
common ocular infection studied), the response rate was 71.4%. The safety of vancomycin 
ointment 1.1% was judged to be satisfactory and no significant tolerability issues were observed.  
In the PMS database, comprising 633 patients evaluable for safety and 519 evaluable for 
efficacy, the clinicians’ overall assessment of the clinical effects of treatment resulted in an 
82.6% efficacy rate overall, across all types of infections. Across the entire safety database, 
serious adverse events (SAEs) were uncommon (14/718 patients); with only two SAEs (corneal 
disorder and corneal erosion) judged to be related to study treatment. Adverse events (AEs) that 
resulted in discontinuation of drug were also uncommon across the entire safety database 
(21/718 patients): eyelid edema, eyelid erythema, corneal erosion, and application site pain were 
the most common AEs leading to discontinuation of drug (each observed in 4/718 patients). The 
most common treatment-related AEs in the Phase 3 study (defined as AEs for which a causal 
relationship to the drug could not be ruled out) were eyelid edema and conjunctival hyperemia 
(each observed in 3/25 patients, 12.0%). The most common adverse drug reactions (ADRs) in 
the PMS study, defined as AEs considered possibly, probably, or remotely related to drug 
administration, were punctate keratitis, corneal erosion, and eyelid edema (each reported in 5 
patients; 0.8%), followed by eyelid erythema (4/633 patients; 0.6%), application site pain (3/633 
patients; 0.5%), and corneal disorder, delayed therapeutic response, and application site 
discomfort (each reported in 2/633 patients; 0.3%). 
The planned Phase 3 clinical trial in the US will evaluate the safety and efficacy of vancomycin 
ointment 1.1% in subjects with moderate to severe unilateral or bilateral bacterial conjunctivitis. 
4.3. 
Justification for Dose, Regimen, and Treatment Period 
The 1% concentration of vancomycin was chosen by Toa Pharmaceuticals to go into Phase 3 
clinical development. In the Phase 1 clinical study, systemic exposure was greater for subjects 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
19 
 
  
who received repeated administration of 2% versus 1% vancomycin, 9 of 10 subjects in the 
2% group had values above the detection limit in the urine as compared to 2 of 10 subjects in the 
1% group. Data from nonclinical toxicity studies also supported the 1% concentration. In 
repeated administration studies in pigmented rabbits, the 3% concentration resulted in 
conjunctival redness and edema whereas the 1% concentration did not produce these effects. 
Another nonclinical study showed that corneal concentrations of vancomycin ophthalmic 
ointment were doubled when administered to Bacillus subtilis-infected eyes as compared to 
normal eyes of Dutch-belted rabbits (Fukuda et al, 2003). Computer simulations predicted QID 
administration of the 2% concentration to rabbits with infected eyes would result in higher 
corneal concentrations than administration of the 3% concentration to rabbits with normal eyes. 
This suggested that administration of the 2% concentration to infected eyes could result in the 
same sort of mild toxicity as the 3% concentration administered to normal eyes. 
The QID dosing regimen utilized in the Phase 3 study conducted by Toa and received by 76% of 
the patients in the PMS database was well tolerated and was efficacious against bacterial 
conjunctivitis. The treatment period in the Toa clinical studies was 14 days. This has been 
modified to 7 days in the current study because the study population will not have refractory 
bacterial infections. Moreover, the disease is viewed to be self-limiting, and a 7-day study 
duration has been utilized in previous studies of drugs approved for this indication. 
4.4. 
Good Clinical Practices Statement 
This study will be conducted according to all stipulations of the protocol, including all 
statements regarding confidentiality, and in compliance with International Conference of 
Harmonisation (ICH) guidelines, and all applicable US federal regulations and local legal and 
regulatory requirements. 
4.5. 
Population to Be Studied 
Study subjects will be male or female subjects, 1 years of age and older, who have clinically 
diagnosed moderate to severe bacterial conjunctivitis, and who have tested negative for 
adenoviral conjunctivitis according to the AdenoPlus® adenovirus test. See Section 7 for 
inclusion and exclusion criteria. Informed consent will be obtained prior to enrollment in the 
trial. 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
20 
 
  
5. 
TRIAL OBJECTIVES AND PURPOSE 
5.1. 
Primary Objective 
The primary objective of this study is to evaluate the safety and efficacy of vancomycin 
hydrochloride ophthalmic ointment 1.1% dosed QID in patients with moderate to severe 
Gram-positive bacterial conjunctivitis.  

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
21 
 
  
6. 
INVESTIGATIONAL PLAN 
6.1. 
Overall Study Design 
This will be a randomized, multicenter, double-masked, placebo-controlled study. Eligible 
subjects will enter the study with clinically diagnosed bacterial conjunctivitis.  
At Screening/Visit 1 (Day 1), subjects will undergo AdenoPlus® conjunctival adenovirus 
screening testing. If the AdenoPlus test result is negative, the subject will undergo microbial 
culture (including susceptibility testing) and ophthalmic evaluations. If the AdenoPlus test result 
is positive, the subject will be considered a screen failure. Subjects confirmed to have met 
eligibility criteria will be randomized to 1 of 2 treatment arms. The subject (or caregiver) will 
administer the allocated study medication QID to the infected eye(s) approximately 4 hours apart 
for 7 days:  
• Vancomycin ophthalmic ointment 1.1% QID 
• Vehicle ointment (placebo) QID 
If both eyes are being treated, the eye with more severe signs of infection (based on the sum of 
the 3 grading scales [conjunctival discharge, bulbar conjunctival injection, and palpebral 
conjunctival injection]) will be considered the study eye. If the sum of the scales for both eyes 
are equal, the default will be the right eye. If a subject with a unilateral infection develops an 
infection in the contralateral eye, the subject should contact the clinical site and will be instructed 
to treat the contralateral eye with the study medication if signs of conjunctival discharge and/or 
injection are present. The eye originally treated will continue to be considered the study eye. 
Only the study eye will be assessed for efficacy; safety assessments will be conducted bilaterally. 
Randomized study medication (vancomycin or vehicle [placebo] ophthalmic ointment) will be 
provided in identical-appearing tubes. The identity of the study medications will be masked to 
the subject, Investigator, study personnel responsible for ophthalmic evaluations, and sponsor 
personnel responsible for medical evaluation of the data. 
If the subject continues to show signs of infection in either eye at Visit 3 (Day 8), the subject will 
be treated per the Investigator’s standard of care. Study treatment will not be administered after 
the last dose on Day 7. 
6.2. 
Number of Subjects 
The study will recruit subjects until the number of subjects with Gram-positive bacterial 
conjunctivitis has reached at least 75 per group. 
6.3. 
Criteria for Study Termination 
The study may be terminated at any time by Kurobe, LLC, following appropriate notification.

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
22 
 
 
  
 
7. 
SELECTION AND WITHDRAWAL OF SUBJECTS 
7.1. 
Subject Inclusion Criteria 
1. Age 1 and older 
2. Clinical diagnosis of acute bacterial conjunctivitis with at least one eye exhibiting 
conjunctival discharge graded ≥ 2 as well as palpebral conjunctival injection graded ≥ 2 
AND bulbar conjunctival injection graded ≥ 2 with onset ≤ 4 days as reported by the 
subject. 
3. Negative test result on AdenoPlus® adenovirus test. 
4. Snellen visual acuity (VA) equal to or better than 20/200 in each eye using current 
corrective lenses, if required (or if worn) and/or using pinhole if subject’s corrective 
lenses are not available at the time of exam. Every attempt should be made to obtain a 
VA measurement in children and, if it is unobtainable, the decision as to whether the 
criterion is met will be at the investigator’s discretion. 
5. Female subjects must be 1-year postmenopausal, surgically sterilized, or women of 
childbearing potential with a negative urine pregnancy test at Visit 1. Women of 
childbearing potential must use an acceptable form of contraception throughout the study. 
Acceptable methods include the use of at least one of the following: intrauterine 
(intrauterine device), hormonal (oral, injection, patch, implant, ring), barrier with 
spermicide (condom, diaphragm), or abstinence. 
6. Able to self-administer study medication or to have the study medication administered by 
a caregiver throughout the study period. 
7. Must have signed written consent from the subject prior to participation in any study-
related procedures if the subject is 18 years of age or older, or from the legally authorized 
representative/guardian if the subject is under 18 years of age. 
8. Must have the signature of the subject on the assent form, as required by Institutional 
Review Board (IRB) guidelines, if the subject is under 18 years of age. 
7.2. 
Subject Exclusion Criteria 
1. Suspected viral or allergic conjunctivitis or suspected fungal or acanthamoeba infections 
at Screening in either eye. 
2. Suspected iritis/uveitis or episcleritis/scleritis at Screening in either eye or history of 
either condition. 
3. Active ulcerative keratitis, specifically any epithelial loss greater than punctate keratitis 
(eg, confluent epithelial loss or any subepithelial infiltration) in either eye. 
4. History of recurrent corneal erosion syndrome, either idiopathic or secondary to previous 
corneal trauma or dry eye syndrome in study eye. 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
23 
 
 
  
 
5. Uncontrolled systemic or debilitating disease (eg, cardiovascular disease, hypertension, 
diabetes, or cystic fibrosis) in the opinion of the Investigator. 
6. Subjects who are immunocompromised (eg, HIV-positive); any use of 
immunosuppressive therapy (including chemotherapy). 
7. Any use of topical ophthalmic medications, including tear substitutes, within 2 hours 
before Screening and throughout the study period in either eye. 
8. Use of topical ophthalmic antimicrobial therapy within 48 hours prior to Screening. Use 
of topical ophthalmic antimicrobial therapy other than study medication is prohibited 
throughout the study period in either eye. 
9. Use of topical ophthalmic anti-inflammatory agents (eg, nonsteroidal anti-inflammatory 
drugs [NSAIDs] or steroids, including steroid-antibiotic combinations) within 48 hours 
prior to Screening and throughout the study period. 
10. Use of systemic antimicrobial therapy for active respiratory tract, urinary tract, skin/soft 
tissue, or otitis media infection within 72 hours prior to Screening and throughout the 
study period. Use of a topical dermatologic antibiotic is permitted. 
11. Use of systemic steroids within 14 days of screening and throughout the study period. 
Inhaled, intranasal, and topical dermatological steroids are permitted. 
12. Contact lens wear during the study period in study eye. (contact lens wear in an untreated 
fellow eye is allowed). 
13. Ocular surgery (nonlaser or laser) within 6 weeks prior to Screening in study eye. 
14. Pregnancy or lactation. 
15. Participation in an ophthalmic drug or device research study within 30 days prior to 
Screening in either eye. 
16. Known hypersensitivity to vancomycin, petrolatum, or mineral oil 
7.3. 
Withdrawal Criteria 
The following are the criteria for considering withdrawal from the study: 
• Withdrawal of subject consent. 
• Subject is lost to follow-up. 
If a subject withdraws or is withdrawn from the study, the principal reason for withdrawal will 
be recorded in the electronic case report form (eCRF).   
If a study subject is lost to follow up at any point during the study period, attempts to contact the 
subject must be documented. 
If a study subject is discontinued from study medication before Day 8 (Visit 3), every effort 
should be made to keep the subject in the study and conduct all study visits as scheduled or, 
failing that, to perform all Day 8 procedures at the visit the subject is discontinued. 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
24 
 
 
  
 
8. 
TREATMENT OF SUBJECTS 
8.1. 
Description of Study Drug 
Vancomycin ophthalmic ointment is formulated as a white to pale yellow ointment containing a 
1.1% concentration of vancomycin hydrochloride in a white petrolatum and mineral oil base 
containing liquid paraffin and white petrolatum, common in commercially available ophthalmic 
ointments. It is contained in an aluminum tube.  
8.2. 
Randomization and Masking 
Study medication will be randomized in a 1:1 ratio (vancomycin ophthalmic ointment 1.1% QID, 
or vehicle ophthalmic ointment [placebo]). A randomized block design will be used and the 
randomization will be created by the biostatistician. 
If subjects meet eligibility criteria (see Section 7) at Screening/Baseline, Visit 1 (Day 1), subjects 
will be randomly assigned to masked study medication. Study sites will assign the next subject 
kit, taken sequentially, from the lowest to the highest numbered kits from within each shipment 
of study medication as directed by Oculos Clinical Research (Oculos). A sufficient supply of 
randomized study medication from the assigned kit to last the duration of the trial will be 
dispensed to the subject after initial dosing at the study site on Day 1. The drug kit randomization 
number will be recorded in the subject’s eCRF. The perforated portion from the 2-part tear-off 
label will be affixed to the Study Drug Accountability Log. 
The study will be double masked. The study medication will be provided in identical-appearing 
boxes with no labeling indicating the identity of the study group or the contents of the tube. The 
boxes will contain identical appearing tubes (see Section 8.1). Study subjects, investigators and 
staff, and study management personnel will be masked to the identity of treatment until after the 
final database lock. 
8.2.1. 
Unmasking During the Study Period 
Should it be necessary to unmask a subject’s treatment assignment in case of emergency, the 
investigator may obtain the treatment code for a given randomized subject from the 2-part 
tear-off label from the subject’s study medication kit. The randomization code is to be obtained 
only if a medical emergency exists and knowledge of the medication being taken will influence 
the medical management of the subject. In the event of emergency or life-threatening condition, 
the investigator may need to unmask the subject. The following procedure should be followed: 
1. The Investigator should contact the Medical Monitor via phone immediately before 
unmasking a subject, unless it is not possible to do so without risk to the subject. 
2. The Investigator should document the SAE and justification for unmasking in the Study 
Summary and Comments pages of the eCRF.  
3. The Subject may continue to participate in the study at the Investigator’s discretion. If the 
subject is to be discontinued from study participation, then ALL procedures described in 
the Early Discontinuation Visit (Section 10.4) should be completed. 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
25 
 
 
  
 
4. The Investigator should contact Oculos at Kurobe-Safety@pointguardllc.com within 
24 hours with the randomization number, subject initials, details of the AE or SAE, any 
action taken, and whether the subject is continuing in the study. 
8.3. 
Concomitant Medications 
8.3.1. 
Permitted Medications and Treatments 
Therapy considered necessary for the subject’s welfare that will not interfere with the evaluation 
of the study medication may be given at the discretion of the Investigator. If there is any question 
as to whether the medication may interfere, the Investigator should contact the Medical Monitor 
or Sponsor. Whenever possible, medications should be administered in dosages that remain 
constant throughout the study duration. 
8.3.2. 
Prohibited Medications 
The Medical Monitor should be notified before prohibited medication or therapy is administered 
unless the safety of the subject requires immediate action. The decision to administer a 
prohibited medication or therapy should be done with the safety of the subject as the primary 
consideration. The Medical Monitor MUST be contacted to determine the permissibility of a 
specific medication or therapy and whether or not the subject should continue with study 
participation. 
Prohibited medications and therapies include: 
• Immunosuppressive therapies, including chemotherapy 
• Topical ophthalmic medications, including tear substitutes, within 2 hours before 
Screening and throughout the study period.  
• Use of topical ophthalmic antimicrobial therapy within 48 hours prior to Screening. 
(Use of topical ophthalmic antimicrobial therapy other than study medication is 
prohibited throughout the study period.) 
• Use of topical ophthalmic anti-inflammatory agents (eg, NSAIDs or steroids, 
including steroid-antibiotic combinations) within 48 hours prior to Screening and 
throughout the study period in either eye. Topical dermatologic steroids are 
permitted. 
• Use of systemic antimicrobial therapy for active respiratory tract, urinary tract, 
skin/soft tissue, or otitis media infection within 72 hours prior to Screening and 
throughout the study period. Use of a topical dermatologic antibiotic is permitted. 
• Use of systemic steroids within 14 days of screening and throughout the study period. 
Inhaled, intranasal, and topical dermatological steroids are permitted. 
8.4. 
Treatment Compliance 
Treatment compliance will be monitored by subject diaries. At Visit 2 (Day 5), site personnel 
will review diaries to assess subject compliance. At Visit 3 (Day 8), the diaries will be collected. 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
26 
 
 
  
 
Data entry into the clinical database will be performed by a designee of Oculos, the clinical 
research organization (CRO) responsible for managing the study. 
8.5. 
Discontinuation of Study Medication 
Subjects may be discontinued from study medication for any of the following reasons: 
• The subject has a clinically significant or serious AE that would not be consistent 
with continuation in the study, as determined by the Investigator or Medical Monitor 
• Pregnancy 
If a subject is discontinued from study medication, every effort should be made to encourage the 
subject to continue to attend study visits to be followed for safety, rather than withdrawing the 
subject from the study. Reasons for considering subject withdrawal from the study are discussed 
in Section 7.3. 
8.6. 
Study Medication Materials and Management 
8.6.1. 
Packaging and Labeling 
Study medication will be packaged and labeled at a central packaging facility. One kit per 
subject will be packed. The kit will contain 2 boxes, and each box will contain 1 tube of 
ointment. Clinical sites are to dispense study medication kits, as directed by Oculos.  
8.6.2. 
Storage  
All study medication kits should be stored under refrigeration, 2-8°C (36-46°F), on initial receipt 
at the clinical site. Once the study medication is dispensed at the Baseline/Screening visit 
(Day 1), it may be stored at room temperature, 20-25°C (68-77°F), in the original packaging, and 
should be protected from light. Subjects will retain all opened and unopened study medication 
materials (tubes and boxes) to return to the site on Day 8. 
8.6.3. 
Administration 
Following randomization, site personnel will dispense study medication and instruct the subject 
(or caregiver, if the subject is not able to self-administer the medication) on administration 
procedures.  

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
27 
 
 
  
 
Steps will include:  
• Washing the hands.  
• Tilting the head back and, pressing the index finger gently on the skin just beneath the 
lower eyelid, pulling the lower eyelid away from the eye to make a space. 
• Squeezing a thin strip of ointment into this space. It should be approximately 1 cm 
(approximately 1/3 inch).  
• Letting go of the eyelid and gently closing the eyes, keeping them closed for 
approximately 1 minute.  
• Avoid touching the applicator tip to any surface (including the eye). After using the 
study medication, wipe the tip of the tube with a clean tissue and keep the tube tightly 
closed. 
• If both eyes are to be dosed, repeat the process for the second eye, beginning with 
washing the hands. 
Study medication will be applied QID, with approximately 4 hours between each dose. 
8.6.4. 
Study Drug Accountability 
The Investigator or designee (eg, study coordinator or pharmacist) will maintain a full 
accountability record for the study medication and will be responsible for recording the receipt, 
dispensing, and return of all supplies of the study drug using the inventories supplied by the 
Sponsor. Each subject’s kit will contain sufficient study medication for the duration of the trial. 
One kit will be dispensed at Screening/Baseline, Visit 1 (Day 1). The Investigator or designee 
will account for all received and returned study medication. The monitor will review dispensing 
and study medication accountability records, as well as subject diaries, during site visits and at 
the completion of the study, and note any discrepancies. All investigational study medication 
must be stored in a secure facility, with access limited to the Investigator and authorized staff.  

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
28 
 
 
  
 
9. 
STUDY ASSESSMENTS 
Prior to entry into the study or initiation of any study related procedures, the patient must read, 
sign, and date the current IRB-approved version of the informed consent form. A full discussion 
of informed consent and the assent process for minors is presented in Section 13.3 . 
9.1. 
Demographic and Background Characteristics 
9.1.1. 
Demographic/Medical History 
Clinically significant/ongoing patient-reported medical/surgical history will be obtained from 
each subject during Visit 1 (Day 1) as part of the eligibility assessment. Demographic 
information including date of birth, gender, race, ethnicity, iris color, and date of informed 
consent will be recorded. 
9.1.2. 
Concomitant Medications History 
All concomitant medications (prescription and over-the-counter [OTC]) taken at Visit 1 (Day 1) 
and for 3 months prior to Visit 1 and throughout the course of the study will be recorded in the 
Concomitant Medications page of the eCRF. Information regarding the dates of first and last 
dose, site of dosing (eg, right eye, left eye, both eyes, systemic), and the reason the concomitant 
medication is being taken must be recorded in the eCRF. When a concomitant medication has 
been taken at a stable dose for longer than 6 months, an estimation of the start date is adequate. 
Standard procedural medications will not go into the eCRF but are recorded on a standard 
procedural medication log provided by Oculos. 
9.1.3. 
Ophthalmic History and Ophthalmic Intervention History 
Clinically significant/ongoing ophthalmic and ophthalmic intervention history will be 
documented and will include previously diagnosed ophthalmic abnormalities and ocular 
surgeries, including laser procedures, as well as previous ocular infections. 
9.1.4. 
Urine Pregnancy Test 
A urine pregnancy test will be performed at Screening/Baseline, Visit 1 (Day 1) and repeated at 
End of Treatment Visit 3 (Day 8) or the Early Discontinuation Visit for women of childbearing 
potential only. 
9.2. 
Efficacy Assessments 
9.2.1. 
Assessment of Clinical Resolution 
9.2.1.1. 
Ocular Discharge 
Conjunctival discharge will be graded on a 4-point scale where 0 = absent, 1 = mild, 
2 = moderate, 3 = severe. 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
29 
 
 
  
 
9.2.1.2. 
Bulbar Conjunctival Injection 
Bulbar conjunctival injection will be graded using the scale below. 
0 
None. May appear blanched to reddish pink without perilimbal injection. Vessels of bulbar 
conjunctiva easily observed 
1 
Mild. A flush, reddish color, predominantly confined to the bulbar conjunctiva 
2 
Moderate. Bright red color of the bulbar conjunctiva 
3 
Severe. Deep, bright diffused redness of the bulbar conjunctiva 
9.2.1.3. 
Palpebral Conjunctival Injection 
Palpebral conjunctival injection will be graded using the scale below. 
0 
None. May appear blanched to reddish pink without perilimbal injection. Vessels of 
palpebral conjunctiva easily observed 
1 
Mild. A flush, reddish color, predominantly confined to the palpebral conjunctiva 
2 
Moderate. Bright red color of the palpebral conjunctiva 
3 
Severe. Deep, bright diffused redness of the palpebral conjunctiva 
 
9.2.1.4. 
Bulbar and Palpebral Conjunctival Injection 
Injection will be graded in both the palpebral and bulbar conjunctiva using the scale below. 
0 
None. May appear blanched to reddish pink without perilimbal injection. Vessels of 
palpebral or bulbar conjunctiva easily observed 
1 
Mild. A flush, reddish color, predominantly confined to the palpebral or bulbar conjunctiva 
2 
Moderate. Bright red color of the palpebral or bulbar conjunctiva 
3 
Severe. Deep, bright diffused redness of the palpebral or bulbar conjunctiva 
9.2.2. 
Assessment of Bacterial Eradication 
A microbial culture will be taken from the study eye at baseline to identify the bacterial species 
present and at each subsequent study visit to assess bacterial eradication, defined as absence of 
all Gram-positive bacterial species that were present at baseline. 
9.3. 
Safety Assessments 
9.3.1. 
Snellen Visual Acuity Assessment 
Snellen VA measurement will be performed at all study visits with the Snellen eye chart using 
the subject’s current corrective lens prescription or pinhole, as applicable, at a distance 
equivalent to 20 feet (6 meters). 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
30 
 
 
  
 
9.3.2. 
Biomicroscopy 
A routine biomicroscopic examination will be performed to evaluate the anterior segment of the 
eye, including lids, cornea, conjunctiva, anterior chamber, iris, and lens. Abnormalities will be 
documented. 
9.4. 
Diagnostic Assessments 
9.4.1. 
AdenoPlus® Test 
RPS AdenoPlus® conjunctival adenovirus test will be performed at the beginning of Visit 1 
(Screening/Baseline). A positive result on the AdenoPlus® test will automatically render the 
subject a screen failure. 
9.5. 
Adverse and Serious Adverse Events 
9.5.1. 
Definition of Adverse Events 
9.5.1.1. 
Adverse Event (AE) 
An AE is any untoward medical occurrence in a patient or clinical study subject administered a 
study medication (pharmaceutical/biological product) that does not necessarily have a causal 
relationship to this medication. An AE can therefore be any unfavorable and unintended sign 
(including abnormal laboratory findings), symptom, or disease temporally associated with the 
use of the study medication, whether or not related to the study medication. Study medication 
includes the investigational drug under evaluation and the comparator product or vehicle placebo 
that is given during any phase of the study. 
Medical conditions/diseases present before starting the investigational treatment are only 
considered AEs if they worsen after starting the investigational treatment. Abnormal test results 
constitute AEs only if they induce clinical signs or symptoms, are considered clinically 
significant, or require therapy. 
The occurrence of AEs should be sought by open-ended questioning of the subject at each visit 
during the study. At each clinic visit, study personnel should ask the following question: "Have 
you had any problems since your last visit?” AEs also may be detected when they are 
volunteered by the subject during or between visits or through study assessments. 
9.5.1.2. 
Serious Adverse Event (SAE) 
An SAE is any untoward medical occurrence that at any dose: 
• Results in death, 
• Is life-threatening, 
Note: The term "life-threatening" refers to an event in which the subject was at risk of death at 
the time of the event; it does not refer to an event which hypothetically might have caused death 
if it were more severe. 
• Results in persistent or significant disability/incapacity (excluding 
progression/outcome of the disease under study); 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
31 
 
 
  
 
• Is a congenital anomaly/birth defect, 
• Requires inpatient hospitalization or prolongation of existing hospitalization, or 
• Is medically significant; ie, defined as an event that jeopardizes the health of the 
subject or may require medical or surgical intervention to prevent one of the 
outcomes listed above. 
Treatment on an outpatient emergency basis that does not result in hospital admission, or a 
hospitalization that is elective or is a preplanned treatment for a pre-existing condition that is 
unrelated to the indication under study and has not worsened since the start of the study, is not 
considered an SAE. 
All SAEs that are ongoing at the time of completion or discontinuation from the study will be 
followed until stabilization or resolution of the event. 
9.6. 
Relationship to Study Drug 
The relationship of AEs to the study medication should be assessed by the Investigator using the 
definitions below. 
Not suspected: The temporal relationship of the event to the study medication makes a causal 
relationship unlikely, or, other drugs, therapeutic interventions or underlying conditions provide 
a sufficient explanation for the observed event. 
Suspected: The temporal relationship of the event to the study medication makes a causal 
relationship possible or other drugs, therapeutic interventions or underlying conditions do not 
provide a sufficient explanation for the observed event. 
If there is any valid reason, even if undetermined, for suspecting a possible cause-and-effect 
relationship between the study medication and the occurrence of the AE, then the AE should be 
considered “suspected.” 
If the relationship between the AE/SAE and the investigational product is determined by the 
Sponsor to be “suspected” the event will be considered to be related to the investigational 
product for the purposes of expedited regulatory reporting (see Section 9.8). 
9.7. 
Recording Adverse Events 
Adverse events spontaneously reported by the subject and/or in response to an open question 
from the study personnel or revealed by observation, regardless of severity or potential 
association with the study medication or study procedures, will be recorded in the eCRF. 
Clinically significant changes in blood pressure and heart rate should be reported as AEs. All 
AEs that occur after a subject has signed the informed consent form until the final study visit, 
Visit 3 (Day 8), should be collected and recorded on the AE eCRF page. Serious adverse events 
will be followed until the event is resolved or stabilized. 
Medical conditions/diseases occurring before the first dose of study medication during Visit 1 
(Day 1) should be collected on the medical/ocular history pages of the eCRF. 
The AE term should be reported in standard medical terminology when possible. For each AE, 
the Investigator will evaluate and report the following: 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
32 
 
 
  
 
• Onset (date and time); 
• Resolution (date and time); 
• Severity grade (mild, moderate, severe); 
• Relationship to study medication (not suspected, suspected); 
• Action taken (none, study medication temporarily interrupted, study medication 
permanently discontinued; concomitant medication taken; hospitalization/prolonged 
hospitalization; other); 
• Serious outcome (yes/no). 
The severity grade should be determined by the Investigator using the definitions below. 
• Mild: Discomfort noticed but no disruption of normal daily activity  
• Moderate: Discomfort sufficient to cause interference with normal daily activity  
• Severe: Incapacitating, with inability to perform normal activities 
It is important to distinguish between serious and severe AEs. Severity is a measure of intensity 
(as defined directly above) whereas seriousness is defined by the criteria under Section 9.5.1.2 . 
An AE of severe intensity may not be considered serious. 
Should a pregnancy occur, it must be reported and recorded on the pregnancy form. Pregnancy in 
itself is not regarded as an AE unless there is a suspicion that an investigational product may 
have interfered with the effectiveness of a contraceptive medication. 
The outcome of all pregnancies (spontaneous miscarriage, elective termination, normal birth or 
congenital abnormality) must be followed up and documented even if the subject was 
discontinued from the study. 
9.8. 
Reporting Adverse Events 
All SAEs (related and unrelated) will be recorded from signing of informed consent until the 
final study visit, Visit 3 (Day 8), following the end of treatment exposure. Any SAEs 
“suspected” to be related to the investigational product and discovered by the Investigator at any 
time after the study should be reported to Oculos.  
Any SAE that occurs must be reported to Oculos within 24 hours of its occurrence or within 
24 hours of learning of its occurrence. Recurrent episodes, complications, or progression of the 
initial SAE must be reported to Oculos as follow-up to the original episode within 24 hours of 
the Investigator receiving the information. Information about all SAEs will be collected and 
recorded on the SAE form. All pertinent medical records and information collected during the 
treatment and follow-up of the subject should be maintained at the site with a copy emailed to 
Kurobe-Safety@pointguardllc.com. The Investigator must assess the SAE relationship and 
complete the SAE form. Oculos may request additional information. Follow-up information (eg, 
discharge summary) will be retained in the subject’s chart and a copy will be emailed to Kurobe-
Safety@pointguardllc.com. 
In addition, all SAEs should be recorded on the Adverse Event eCRF page with the serious 
question marked “Yes”. 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
33 
 
 
  
 
It is the investigator’s responsibility to notify the approving IRB of any SAEs on a timely basis 
as instructed by the Sponsor following the Sponsor’s determination of causality. 
All subjects who experience an SAE should be followed clinically and undergo the appropriate 
diagnostic evaluations until stabilization or resolution of the event. 
Kurobe will report all SAEs to the US Food and Drug Administration (FDA) on the appropriate 
schedule depending if the event is drug related or not drug related, expected, unexpected (based 
on the available information in the Investigator’s Brochure). 
Any death occurring during the study and follow up period should be reported as an SAE. For 
any death occurring through the end of the study, regardless of the degree of relationship to study 
drug, the SAE resulting in the death must be reported to Oculos. A death occurring after 
completion of the study at Visit 3 (Day 8) that is not reasonably associated with study drug 
administration, does not require completion of the SAE form. 
 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
34 
 
 
  
 
10. 
STUDY ACTIVITIES 
10.1. 
Visit 1 (Day 1)/Screening/Baseline 
At Visit 1 (Day 1) subjects will provide informed consent/assent before any study-related 
procedures are conducted and participate in screening procedures (AdenoPlus® conjunctival 
adenovirus test, microbial culture, ophthalmic assessments including grading of clinical signs) to 
establish eligibility for the study. Subjects deemed eligible (subjects who are clinically diagnosed 
with bacterial conjunctivitis, and who have met the inclusion/exclusion criteria) will be 
randomized into the study and dispensed medication. Subjects (or caregivers) will receive 
instruction and then administer the first dose of allocated study medication at the site. Visit 1 
procedures include: 
• Informed consent 
• Demographics information 
• Medical/ocular history 
• Prior/concomitant medication review 
• AdenoPlus conjunctival adenovirus test 
• Snellen VA using current corrective lenses and/or pinhole as applicable 
• Biomicroscopy 
• Grading of conjunctival discharge 
• Grading of bulbar conjunctival injection 
• Grading of palpebral conjunctival injection 
• Microbial culture / susceptibility testing  
• Urine pregnancy test (for females of childbearing potential only) 
• Inclusion/exclusion review 
• Randomization 
• Dispense study medication 
• Study medication administration at site 
• Adverse event assessment 
All 4 doses should be administered on Day 1 even if the intervals are shorter than 4 hours 
between doses. On Days 2-4 subjects will continue to administer the randomized study 
medication QID (approximately 4 hours between doses). On Day 5, subjects will return to the 
site for Visit 2. Subjects should be reminded to bring the study diary to the clinical site at Visit 2 
(Day 5). 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
35 
 
 
  
 
10.2. 
Visit 2/Treatment 
At Visit 2 (Day 5 [± 1 day]), study site personnel will conduct diary review. Subjects will 
participate in microbial culture and ophthalmic assessments of safety and efficacy. Microbial 
culture results (including Gram-positive and MRSA/MRSE status) will be reviewed and noted in 
the eCRF. 
Visit 2 procedures include: 
• Concomitant medication review 
• Study diary review 
• Snellen VA using current corrective lenses and/or pinhole as applicable 
• Biomicroscopy 
• Grading of conjunctival discharge 
• Grading of bulbar conjunctival injection 
• Grading of palpebral conjunctival injection 
• Microbial culture 
• Adverse event assessment 
Subjects should administer all 4 doses on Day 5 even if the intervals are shorter than 4 hours 
between doses. On Days 6-7 subjects will administer the randomized study medication QID 
(approximately 4 hours between doses). On Day 8, subjects will return to the site for Visit 3. 
Subjects are to be reminded not to dose after their fourth dose on Day 7 and to bring all study 
medication materials and the study diary to the clinical site at Visit 3 (Day 8). 
10.3. 
Visit 3/End of Treatment 
At Visit 3, Day 8 (+ 1 day) subjects will return all study medication to the clinical site. Study site 
personnel will conduct diary review and study drug accountability procedures. Subjects will 
participate in final ophthalmic assessments of safety and efficacy. 
Visit 8 procedures include: 
• Concomitant medication review 
• Study diary review 
• Snellen VA using current corrective lenses and/or pinhole as applicable 
• Biomicroscopy 
• Grading of conjunctival discharge 
• Grading of bulbar conjunctival injection 
• Grading of palpebral conjunctival injection 
• Microbial culture 
• Urine pregnancy test 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
36 
 
 
  
 
• Adverse event assessment 
• Collect opened and unopened study medication 
If the subject continues to show signs of infection in either eye at Visit 3 (Day 8), the subject will 
be treated per the Investigator’s standard of care. Study treatment will not be administered after 
the last dose on Day 7. 
10.4. 
Early Discontinuation 
If a study subject is discontinued from study medication before Visit 3 (Day 8) but after Visit 1 
(Day 1), every effort should be made to perform all of the following procedures that were not 
previously conducted at the visit during which the subject was discontinued: 
Early termination procedures include: 
• Concomitant medication review 
• Study diary review 
• Snellen VA using current corrective lenses and/or pinhole as applicable 
• Biomicroscopy 
• Grading of conjunctival discharge 
• Grading of bulbar conjunctival injection 
• Grading of palpebral conjunctival injection 
• Microbial culture 
• Urine pregnancy test 
• Adverse event assessment 
• Collect opened and unopened study medication 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
37 
 
 
  
 
11. 
STATISTICS 
11.1. 
General Considerations 
This will be a randomized, multicenter, double-masked, active- and placebo-controlled study. 
Eligible subjects will enter the study with unilateral or bilateral moderate to severe bacterial 
conjunctivitis. At Screening/Baseline, Visit 1 (Day 1), subjects will undergo AdenoPlus® 
conjunctival adenovirus screening testing. If the AdenoPlus test result is negative, the subject 
will undergo microbial culture (including susceptibility testing) and ophthalmic evaluations. If 
the AdenoPlus test result is positive, the subject will be considered a screen failure. Subjects 
confirmed to have met eligibility criteria will be randomized to 1 of 2 treatment arms and will 
administer the allocated study medication QID to the infected eye(s) approximately 4 hours apart 
for 7 days: 
• Vancomycin ophthalmic ointment 1.1% QID 
• Vehicle ointment (placebo) QID 
A biostatistician will perform statistical analyses as agreed with the Sponsor according to the 
Statistical Analysis Plan. Any additional or supplemental data analysis performed independently 
by an investigator shall be submitted to the Sponsor for review. 
The analysis of continuous and ordinal variables will use the applicable parametric methods 
(t-test, analysis of variance [ANOVA], analysis of covariance [ANCOVA]). Descriptive 
statistics will be used to summarize continuous outcomes (number of subjects [N], mean, 
standard deviation or standard error of the mean, median, maximum, and minimum) and 
categorical variables (frequency and percentage) at each assessment time point. (The time points 
at which data are collected are specified in the schedule of observations—see Table 2) 
Within-group changes for continuous and categorical outcomes will be assessed using 
95% confidence intervals (CIs). 
All subjects with clinically diagnosed bacterial conjunctivitis will be treated and followed, but 
only those eyes with Gram-positive bacterial conjunctivitis will be included in the primary 
analysis of efficacy. 
11.2. 
Determination of Sample Size 
A two group chi-square test with a 0.05 two-sided significance level will have 90% power to 
detect the difference between a Group 1 proportion of 0.75 and a Group 2 proportion of 0.50 
(odds ratio of 3.0) when the sample size in each group is 77. The mITT population of the active 
treatment group will be compared to the mITT population of the vehicle group. 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
38 
 
 
  
 
11.3. 
Analysis Populations 
11.3.1. 
Populations for Efficacy Analysis 
11.3.1.1. Intent-to-Treat (ITT) Population 
The intent-to-treat (ITT) population is defined as all randomized subjects. An ITT analysis with 
LOCF for missing data will be conducted as a secondary efficacy analysis for all efficacy 
endpoints. 
11.3.1.2. Modified Intent-to-Treat (mITT) Population 
The modified intent-to-treat (mITT) population consists of those subjects in the ITT population 
who have Gram-positive bacterial conjunctivitis. 
11.3.2. 
Per Protocol Analyses 
The per protocol population will consist of those subjects in the mITT who are compliant in 
dosing, meeting study visits and without significant protocol violations.  
11.3.3. 
Population for Safety Analysis 
The safety analysis population is defined as all randomized subjects who received at least one 
dose of the allocated study medication. Both eyes will be analyzed. 
11.4. 
Demographics and Baseline Characteristics 
Subject demographic and baseline characteristics will be summarized for the ITT analysis 
population; however, should there be a reasonable difference in the size of the ITT and safety 
analysis populations, demographic and baseline characteristics will be summarized for both. The 
comparability of groups used in comparison analyses will be characterized in tables of 
demographic data. Summary tables will be supported with individual subject data listings. 
11.5. 
Efficacy Analysis 
Efficacy analyses will be performed on Visit 3 (Day 8).  
Efficacy data will be presented in tables of descriptive statistics and frequency distribution. All 
summary tables will be supported with individual subject data listings. 
For the primary efficacy analysis, those who require rescue interventions or who are lost to 
follow up will be considered treatment failures. 
11.5.1. 
Primary Endpoint 
The primary endpoints comprise a set of hypotheses that will be tested in a hierarchical fashion. 
The primary efficacy endpoints are: proportion of subjects at Visit 3 (Day 8) with: 
• Clinical resolution of bacterial conjunctivitis (defined as absence of conjunctival 
discharge, bulbar conjunctival injection and palpebral conjunctival injection) 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
39 
 
 
  
 
• Microbial eradication (absence of all Gram-positive bacterial species present at 
baseline) 
The difference in proportion in the two treatment groups will be tested by the chi-square test with 
a significance level of 0.05. In order to control the Type I error rate these two endpoints will be 
tested sequentially in the order described above. If the null hypothesis for the clinical resolution 
endpoint can be rejected at P ≤ 0.05, the bacterial eradication endpoint will be tested at P ≤ 0.05 
11.6. 
Safety Analyses 
Safety assessments will include VA using current corrective lenses and/or pinhole, if applicable, 
slit lamp examination (both conducted bilaterally), urine pregnancy test (for women of 
childbearing potential only), and collection of adverse events.  
Safety data will be presented in tables of descriptive statistics and frequency distribution. All 
summary tables will be supported with individual subject data listings. 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
40 
 
 
  
 
12. 
QUALITY CONTROL AND QUALITY ASSURANCE 
Oculos Clinical Research/Kurobe, LLC and/or their contracted agents utilize standard operating 
procedures (SOPs) designed to ensure that research procedures and documentation are 
consistently conducted/prepared to the highest quality standards. These SOPs require compliance 
with FDA regulations and the ICH Good Clinical Practice (GCP) guidance. 
The study will be monitored by Oculos to verify that the rights and well-being of human subjects 
are being protected, the reported data are accurate, complete, and verifiable, and that the conduct 
of the study is in compliance with the currently approved protocol, with ICH GCP, and with the 
applicable regulatory requirements. 
To insure compliance with GCP and all applicable regulatory requirements, Kurobe or its agent 
may conduct a quality assurance audit at any time during or after completion of a study. The 
investigator will be given adequate notice if he/she is selected for an audit. The audit will 
include, but is not limited to: a review of all informed consent forms, medical records, and 
regulatory documentation; an assessment of study conduct and protocol compliance; and a 
review of the investigational drug product receipt, storage, and administration. At the conclusion 
of an audit, the auditor will conduct a brief meeting with the investigator to review the findings 
of the audit. 
 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
41 
 
 
  
 
13. 
ADMINISTRATIVE CONSIDERATIONS 
13.1. 
Institutional Review Board (IRB) 
The IRB must review, approve, and provide continuing review of the clinical study protocol, 
protocol amendments, the informed consent documents, subject recruitment advertisements, and 
any other written information to be provided to the subjects. Initial IRB approval is an 
affirmative decision that the clinical study has been reviewed and may be conducted at the study 
site within the constraints set forth by the IRB, the institution, GCP, and applicable regulatory 
requirements. A copy of the IRB approval letter for the protocol, the informed consent, minor 
assent, the intended advertising, and any written material to be provided to the subject must be 
submitted to Oculos prior to release of investigational supplies to the study site. Progress reports 
and notifications of serious adverse drug reactions will be provided to the IRB or IEC according 
to local regulations and guidelines. The IRB must be notified of completion or termination of the 
study. The study site must maintain an accurate and complete record of all reports, documents, 
and other submissions made to the IRB concerning this protocol. 
13.2. 
Ethical Conduct of the Study 
The study will be conducted according to all stipulations of the protocol, including all statements 
regarding confidentiality, and in compliance with ICH guidelines, and all applicable US federal 
regulations and local legal and regulatory requirements. 
13.3. 
Written Informed Consent 
A sample informed consent form containing the required elements of informed consent will be 
provided by Oculos.  Sample minor assent form(s) will be provided as required by IRB 
guidelines. Any changes made to these samples must be approved by Oculos prior to submission 
to the IRB. After approval by Oculos, the informed consent and minor assent forms must be 
submitted to and approved by the IRB. The informed consent must be written in a language in 
which the subject is fluent.  The minor assent form(s) will be written as required by IRB 
guidelines. Regulations require that foreign language informed consent and assent forms be 
submitted to the IRB for approval. The foreign language translation is required to contain a 
statement of certification of the translation. The investigator must forward a copy of the consent 
and assent forms, the certified foreign language translation, and an IRB approval letter to Oculos. 
It is the responsibility of the Investigator to inform each subject of the purpose of this clinical 
trial, including possible risks and benefits, and to document the informed consent/assent process. 
Prior to undergoing any study-related procedures, the subject must read, sign, and date the 
current IRB-approved version of the informed consent form. For minor subjects ages 7-17, the 
assent form must be signed and dated per IRB guidelines. The original informed consent/assent 
form is to be retained by the study site, and a copy is to be given to the subject. 
13.4. 
Subject Confidentiality and Confidentiality of Data 
Data generated for the study should be stored in a limited-access file area and be accessible only 
to representatives of the study site, Oculos/Kurobe, LLC, the IRB, and FDA/relevant regulatory 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
42 
 
 
  
 
agencies. Medical information resulting from a subject’s participation in this study may be given 
to the subject’s personal physician or to the appropriate medical personnel responsible for the 
subject’s welfare. No information that can be related to a specific individual subject will be 
released or used in any fashion without the signed written consent of that subject. All reports and 
communications relating to study subjects will identify subjects only by initials and subject 
identification number. Complete subject identification will be kept by the Investigator for 
purposes of long-term follow-up, if needed. This information will be treated with strict 
adherence to professional standards of confidentiality. 
13.5. 
Study Monitoring 
The study will be monitored by Oculos to assure compliance with the study protocol and the 
quality of the data collected. Monitoring visits may occur as required and could include a study 
initiation visit, a monitoring visit, and a study close-out visit. Training will be provided for key 
investigative personnel in all aspects of study conduct. 
During visits to the study site, the monitor may review the source documents including but not 
limited to signed informed consent forms, patient diaries, study medication accountability and 
storage, and the reporting procedures for AEs and SAEs. All data generated during this study and 
the medical records/documents from which they originated are subject to inspection by Oculos, 
the study Sponsor, the FDA, and other regulatory agencies. The investigator must notify Oculos 
promptly of any inspections scheduled by regulatory authorities. 
Upon completion of the study, the clinical monitor will conduct a final visit (closeout) to the site. 
The objectives of this visit are to ascertain that all regulatory records and reports are complete, 
verify that the study drug and other supplies have been accounted for, and ensure that the 
investigators are aware of their responsibilities once the study ends.  
The Investigator is responsible for permitting the Sponsor direct access to any study documents 
for monitoring and auditing purposes, for providing adequate space for monitoring, and for 
addressing any questions or issues that might be raised by the monitor or auditor on a timely 
basis. 
13.6. 
Case Report Forms and Study Records  
All data relating to study procedures will be entered by site personnel directly onto eCRFs 
provided by Oculos. The eCRF is the first place the majority of the study data will be recorded; 
therefore, the electronic data captured will be the source. In general, paper source documents will 
not be created, but when generated, source documents (eg, original patient diaries, discharge 
summaries, etc.) will be retained at the study site. 
13.7. 
Protocol Violations/Deviations 
The Investigator should not deviate from the requirements of this protocol without prior written 
approval of the Medical Monitor at Oculos, with the exception of a medical emergency. 
A significant protocol violation must be reported to Oculos upon discovery. Protocol deviations 
should be reported to the IRB in accordance with IRB guidelines. 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
43 
 
 
  
 
All changes to the protocol will be made by Kurobe, LLC, or designee as an approved 
amendment to the protocol, submitted to the FDA, and approved by the IRB prior to 
implementation.  
13.8. 
Access to Source Documentation 
A trial-related monitoring audit, review by the IRB, and/or regulatory inspection may be 
conducted at any time during or after completion of a study. The Investigator will be given 
adequate notice if he/she is selected for an audit and must provide direct access to study 
documentation. The audit may include, but is not limited to, a review of all informed consent 
forms; a review of medical records; a review of regulatory documentation; an assessment of 
study conduct and protocol compliance; and a review of the investigational drug product receipt, 
storage, and administration. 
13.9. 
Data Generation and Analysis 
Management of data and the production of the clinical study report will be the responsibility of 
Kurobe. 
During the course of the trial, data queries will be generated for data items that are potentially 
erroneous and require appropriate clarification or correction. Such clarifications and corrections 
will be discussed with and approved by study site personnel and appropriately documented. Prior 
to database lock, data listings will be generated and anomalous values investigated. 
13.9.1. 
Retention of Data 
All study-related records must be maintained for at least 2 years after a marketing application is 
approved for the drug. If an application is not approved for the drug, all study-related records 
must be maintained until at least 2 years after shipment and delivery of the drug for 
investigational use is discontinued and FDA or regulatory agencies have been so notified. The 
investigator will not discard any records without notifying Kurobe. If the principal investigator 
moves from the current study site, Kurobe should be notified of the name of the person who will 
assume responsibility for maintenance of the records at the study site or the new address at which 
the records will be stored. The investigator will notify Kurobe as soon as possible in the event of 
accidental loss or destruction of any study documentation. 
If it becomes necessary for Oculos/Kurobe or the FDA or relevant regulatory authority to review 
any documentation relating to the study, the Investigator must permit access to such records. 
13.10. 
Publication and Disclosure Policy 
All information concerning KUR-1301 and the operations of Kurobe, LLC, such as patent 
applications, formulas, manufacturing processes, basic scientific data or formulation information 
not previously published, are considered CONFIDENTIAL and shall remain the sole property of 
Kurobe, LLC The Investigator agrees to use this information only in accomplishing this study 
and will not use it for other purposes without the written consent of Kurobe, LLC 
The publication policy is addressed in a separate agreement. 

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
44 
 
 
  
 
14. 
LIST OF REFERENCES 
Adebayo A, Parikh JG, McCormick SA, Shah MK, Huerto RS, Yu G, Milman T. Shifting trends 
in in vitro antibiotic susceptibilities for common bacterial conjunctival isolates in the last decade 
at the New York Eye and Ear Infirmary. Graefes Arch Clin Exp Ophthalmol. 2011 
Jan;249(1):111-9. 
Asbell PA, Colby KA, Deng S, McDonnell P, Meisler DM, Raizman MB, et al. Ocular TRUST: 
nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol. 2008 
Jun;145(6):951-958. (Asbell et al, 2008a) 
Asbell PA, Sahm DF, Shaw M, Draghi DC, Brown NP. Increasing prevalence of methicillin 
resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 
2000 to 2005. J Cataract Refract Surg. 2008 May;34(5):814-8.(Asbell et al, 2008b) 
Barbault S, Aymard G, Feldman D, Pointereau-Bellanger A, Thuillier A. Stability of 
vancomycin eye drops. Journal de Pharmacie Clinique. 1999 Jun;18(2):183-9. 
Blomquist PH. Methicillin-resistant Staphylococcus aureus infections of the eye and orbit (an 
American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006;104:322-45. 
Brennen C, Muder RR. Conjunctivitis associated with methicillin-resistant Staphylococcus 
aureus in a long-term-care facility. Am J Med. 1990 May;88(5N):14N-17N. 
Cavuoto K, Zutshi D, Karp CL, Miller D, Feuer W. Update on bacterial conjunctivitis in South 
Florida. Ophthalmology. 2008 Jan;115(1):51-6. Epub 2007 Jun 18. 
Eiferman RA, O'Neill KP, Morrison NA. Methicillin-resistant Staphylococcus aureus corneal 
ulcers. Ann Ophthalmol. 1991 Nov;23(11):414-5. 
Freidlin J, Acharya N, Lietman TM, Cevallos V, Whitcher JP, Margolis TP. Spectrum of eye 
disease caused by methicillin-resistant Staphylococcus aureus. Am J Ophthalmol. 2007 
Aug;144(2):313-5. 
Fleischer AB, Hoover DL, Khan JA, Parisi JT, Burns RP. Topical vancomycin formulation for 
methicillin-resistant Staphylococcus epidermidis blepharoconjunctivitis. Am J Ophthalmol. 1986 
Mar 15;101(3):283-7. 
Fuhrman LC Jr, Stroman RT. Stability of vancomycin in an extemporaneously compounded 
ophthalmic solution. Am J Health Syst Pharm. 1998 Jul 1;55(13):1386-8. 
Fukuda M, Hanazome I, Sasaki K. The intraocular dynamics of vancomycin hydrochloride 
ophthalmic ointment (TN-011) in rabbits. J Infect Chemother. 2003 Mar;9(1):93-6.  
Goodman DF, Gottsch JD. Methicillin-resistant Staphylococcus epidermidis keratitis treated 
with vancomycin. Arch Ophthalmol. 1988 Nov;106(11):1570-1. PubMed PMID: 3190543. 
Haas W, Pillar CM, Torres M, Morris TW, Sahm DF. Monitoring antibiotic resistance in ocular 
microorganisms: results from the Antibiotic Resistance Monitoring in Ocular micRorganisms 
(ARMOR) 2009 surveillance study. Am J Ophthalmol. 2011 Oct;152(4):567-574.e3 
Khan JA, Hoover D, Ide CH. Methicillin-resistant Staphylococcus epidermidis blepharitis. Am J 
Ophthalmol. 1984 Nov;98(5):562-5.  

Vancomycin Hydrochloride Ophthalmic Ointment 
Kurobe, LLC 
Protocol KUR-1301-101 Amendment 2 
 
IND 119356 
 
 
45 
 
 
  
 
Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, et al; Active Bacterial Core 
surveillance (ABCs) MRSA Investigators. Invasive methicillin-resistant Staphylococcus aureus 
infections in the United States. JAMA. 2007 Oct 17;298(15):1763-71. 
Lee KM, Lee HS, Kim MS. Two cases of corneal ulcer due to methicillin-resistant 
Staphylococcus aureus in high risk groups. Korean J Ophthalmol. 2010 Aug;24(4):240-4. 
Miller D, Diaz MG, Perez EM. Prevalence of community acquired methicillin-resistant 
Staphylococcus aureus among ocular MRSA isolates. Am J Infect Control 2006;34(5):E23–4. 
Ness T, Schneider C. Endogenous endophthalmitis caused by methicillin-resistant 
Staphylococcus aureus (MRSA). Retina. 2009 Jun;29(6):831-4. 
Rubinfeld RS, Negvesky GJ. Methicillin-resistant Staphylococcus aureus ulcerative keratitis 
after laser in situ keratomileusis. J Cataract Refract Surg. 2001 Sep;27(9):1523-5. PubMed 
PMID: 11566544. 
Rutar T, Chambers HF, Crawford JB, Perdreau-Remington F, Zwick OM, Karr M, et al. 
Ophthalmic manifestations of infections caused by the USA300 clone of community-associated 
methicillin-resistant Staphylococcus aureus. Ophthalmology. 2006 Aug;113(8):1455-62. 
Rutar T, Zwick OM, Cockerham KP, Horton JC. Bilateral blindness from orbital cellulitis caused 
by community-acquired methicillin-resistant Staphylococcus aureus. Am J Ophthalmol. 2005 
Oct;140(4):740-2.  
Sautou-Miranda V, Libert F, Grand-Boyer A, Gellis C, Chopineau J. Impact of deep freezing on 
the stability of 25 mg/ml vancomycin ophthalmic solutions. Int J Pharm. 2002 Mar 2;234(1-
2):205-12. 
Sotozono C, Fukuda M, Ohishi M, Yano K, Origasa H, Saiki Y, et al. Vancomycin Ophthalmic 
Ointment 1% for methicillin-resistant Staphylococcus aureus or methicillin-resistant 
Staphylococcus epidermidis infections: a case series. BMJ Open. 2013 Jan 29;3(1). 
Sotozono C, Inagaki K, Fujita A, Koizumi N, Sano Y, Inatomi T, et al. Methicillin-resistant 
Staphylococcus aureus and methicillin-resistant Staphylococcus epidermidis infections in the 
cornea. Cornea. 2002 Oct;21(7 Suppl):S94-101. PubMed PMID: 12484707. 
Vancocin [package insert]. Exton, PA: ViroPharma, Inc; 2011.